A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular risk in a genetically defined population with a recent Acute Coronary Syndrom (ACS): The dal-GenE Trial. The purpose of this study is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in subjects with a documented recent Acute Coronary Syndrome and the AA genotype at variant rs 1967309 in the ADCY9 gene.


Essentia Health Duluth



For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 06/23/2016

Research Study Categories

  • Adult Studies


  • Cardiology
Clinical Trials at 866-839-4128
or clinicaltrials@eirh.org

Like most websites, we use cookies and other technologies to keep our website reliable, secure, and to better understand how our site is used. By using our site, you agree to our use of these tools. Learn more.